Functional subsets of mesenchymal cell types in the tumor microenvironment

Seminars in Cancer Biology

Volumn 25, Issue , 2014, Pages 3-9

  Cortez, Eliane ^a   Roswall, Pernilla ^b   Pietras, Kristian ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer associated fibroblast; Mesenchymal cells; Pericyte; Tumor microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; DESMIN; ENDOSIALIN; FIBROBLAST GROWTH FACTOR 2; GLIAL ANTIGEN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KERATINOCYTE GROWTH FACTOR; MEMBRANE PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; REGULATOR OF G PROTEIN SIGNALING 5; SEPRASE; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; CALCIUM BINDING PROTEIN; FSP1 PROTEIN, HUMAN; GELATINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SERINE PROTEINASE; TUMOR MARKER;

CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CELL FUNCTION; CELL TYPE; CELLULAR DISTRIBUTION; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; MESENCHYME CELL; MYOFIBROBLAST; NONHUMAN; PERICYTE; PLASTICITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; TUMOR MICROENVIRONMENT; VASCULAR SMOOTH MUSCLE; ANIMAL; MESENCHYMAL STROMA CELL; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CALCIUM-BINDING PROTEINS; FIBROBLASTS; GELATINASES; HUMANS; MEMBRANE PROTEINS; MESENCHYMAL STROMAL CELLS; NEOPLASMS; PERICYTES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84897476556     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.12.010     Document Type: Review

References (80)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49(6):1374-1403.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
3. Pietras K., Östman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010, 316(8):1324-1331.
4. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21(3):309-322.
5. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12(2):133-143.
6. Geudens I., Gerhardt H. Coordinating cell behaviour during blood vessel formation. Development 2011, 138(21):4569-4583.
7. De Palma M., Lewis C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23(3):277-286.
8. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6(5):392-401.
9. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15(1):21-34.
10. Tsujino T., Seshimo I., Yamamoto H., Ngan C.Y., Ezumi K., Takemasa I., et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 2007, 13(7):2082-2090.
11. Fuyuhiro Y., Yashiro M., Noda S., Kashiwagi S., Matsuoka J., Doi Y., et al. Myofibroblasts are associated with the progression of scirrhous gastric carcinoma. Exp Ther Med 2010, 1(4):547-551.
12. Surowiak P., Murawa D., Materna V., Maciejczyk A., Pudelko M., Ciesla S., et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res 2007, 27(4C):2917-2924.
13. Sugimoto H., Mundel T.M., Kieran M.W., Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006, 5(12):1640-1646.
14. Anderberg C., Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle 2009, 8(10):1461-1462.
15. Anderberg C., Li H., Fredriksson L., Andrae J., Betsholtz C., Li X., et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009, 69(1):369-378.
16. Roswall P., Pietras K. Of mice and men: a comparative study of cancer-associated fibroblasts in mammary carcinoma. Ups J Med Sci 2012, 117(2):196-201.
17. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563.
18. Qian H., Badaloni A., Chiara F., Stjernberg J., Polisetti N., Nihlberg K., et al. Molecular characterization of prospectively isolated multipotent mesenchymal progenitors provides new insight into the cellular identity of mesenchymal stem cells in mouse bone marrow. Mol Cell Biol 2013, 33(4):661-677.
19. Zhang H., Maric I., Diprima M.J., Khan J., Orentas R.J., Kaplan R.N., et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 2013, 122(7):1105-1113.
20. Garin-Chesa P., Old L.J., Rettig W.J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990, 87(18):7235-7239.
21. Bae S., Park C.W., Son H.K., Ju H.K., Paik D., Jeon C.J., et al. Fibroblast activation protein alpha identifies mesenchymal stromal cells from human bone marrow. Br J Haematol 2008, 142(5):827-830.
22. Scanlan M.J., Raj B.K., Calvo B., Garin-Chesa P., Sanz-Moncasi M.P., Healey J.H., et al. Molecular cloning of fibroblast activation protein alpha: a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994, 91(12):5657-5661.
23. Pineiro-Sanchez M.L., Goldstein L.A., Dodt J., Howard L., Yeh Y., Tran H., et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997, 272(12):7595-7601.
24. Christiansen V.J., Jackson K.W., Lee K.N., Downs T.D., McKee P.A. Targeting inhibition of fibroblast activation protein-alpha and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia 2013, 15(4):348-358.
25. Lee H.O., Mullins S.R., Franco-Barraza J., Valianou M., Cukierman E., Cheng J.D. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011, 11:245.
26. Wikberg M.L., Edin S., Lundberg I.V., Van Guelpen B., Dahlin A.M., Rutegard J., et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol 2013, 34(2):1013-1020.
27. Shi M., Yu D.H., Chen Y., Zhao C.Y., Zhang J., Liu Q.H., et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol 2012, 18(8):840-846.
28. Saadi A., Shannon N.B., Lao-Sirieix P., O'Donovan M., Walker E., Clemons N.J., et al. Stromal genes discriminate preinvasive from invasive disease: predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 2010, 107(5):2177-2182.
29. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330(6005):827-830.
30. Liao D., Luo Y., Markowitz D., Xiang R., Reisfeld R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009, 4(11):7965.
31. Santos A.M., Jung J., Aziz N., Kissil J.L., Pure E. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009, 119(12):3613-3625.
32. Cabezon T., Celis J.E., Skibshoj I., Klingelhofer J., Grigorian M., Gromov P., et al. Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Cancer 2007, 121(7):1433-1444.
33. Grum-Schwensen B., Klingelhofer J., Berg C.H., El-Naaman C., Grigorian M., Lukanidin E., et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 2005, 65(9):3772-3780.
34. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303(5659):848-851.
35. O'Connell J.T., Sugimoto H., Cooke V.G., MacDonald B.A., Mehta A.I., LeBleu V.S., et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA 2011, 108(38):16002-16007.
36. Zhang J., Chen L., Xiao M., Wang C., Qin Z. FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation. Am J Pathol 2011, 178(1):382-390.
37. Zhang J., Chen L., Liu X., Kammertoens T., Blankenstein T., Qin Z. Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens. Cancer Res 2013, 73(9):2770-2781.
38. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22(10):1276-1312.
39. Pietras K., Sjoblom T., Rubin K., Heldin C.H., Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003, 3(5):439-443.
40. Shao Z.-M., Nguyen M., Barsky S.H. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 2000, 19(38):4337-4345.
41. Pietras K., Pahler J., Bergers G., Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008, 5(1):e19.
42. Ehnman M., Missiaglia E., Folestad E., Selfe J., Strell C., Thway K., et al. Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 2013, 73(7):2139-2149.
43. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17(2):135-147.
44. Forsberg K., Valyi-Nagy I., Heldin C.-H., Herlyn M., Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 1993, 90(2):393-397.
45. Skobe M., Fusenig N.E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 1998, 95(3):1050-1055.
46. Pena C., Cespedes M.V., Lindh M.B., Kiflemariam S., Mezheyeuski A., Edqvist P.H., et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res 2013, 73(4):1287-1297.
47. Shinagawa K., Kitadai Y., Tanaka M., Sumida T., Onoyama M., Ohnishi M., et al. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int J Cancer 2013, 132(4):813-823.
48. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R.K., Heldin C.H., et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001, 61(7):2929-2934.
49. Pietras K., Rubin K., Sjöblom T., Buchdunger E., Sjöquist M., Heldin C.H., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62(19):5476-5484.
50. Falcon B.L., Pietras K., Chou J., Chen D., Sennino B., Hanahan D., et al. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol 2011, 178(6):2920-2930.
51. Paulsson J., Sjoblom T., Micke P., Ponten F., Landberg G., Heldin C.H., et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009, 175(1):334-341.
52. Podhajcer O.L., Benedetti L.G., Girotti M.R., Prada F., Salvatierra E., Llera A.S. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008, 27(4):691-705.
53. Nolan-Stevaux O., Lau J., Truitt M.L., Chu G.C., Hebrok M., Fernandez-Zapico M.E., et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009, 23(1):24-36.
54. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22(5):571-584.
55. Lindskog H., Athley E., Larsson E., Lundin S., Hellstrom M., Lindahl P. New insights to vascular smooth muscle cell and pericyte differentiation of mouse embryonic stem cells in vitro. Arterioscler Thromb Vasc Biol 2006, 26(7):1457-1464.
56. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005, 97(6):512-523.
57. Ozerdem U., Grako K.A., Dahlin-Huppe K., Monosov E., Stallcup W.B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn 2001, 222(2):218-227.
58. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFR beta(+) perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7(9):870-U16.
59. Cooke V.G., LeBleu V.S., Keskin D., Khan Z., O'Connell J.T., Teng Y., et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21(1):66-81.
60. Lindahl P., Johansson B.R., Levéen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277(5323):242-245.
61. Hellstrom M., Kalen M., Lindahl P., Abramsson A., Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 1999, 126(14):3047-3055.
62. Lindblom P., Gerhardt H., Liebner S., Abramsson A., Enge M., Hellstrom M., et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003, 17(15):1835-1840.
63. Franco M., Roswall P., Cortez E., Hanahan D., Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011, 118(10):2906-2917.
64. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295.
65. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005, 23(5):939-952.
66. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18(2):338-340.
67. Franco M., Paez-Ribes M., Cortez E., Casanovas O., Pietras K. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy. Horm Metab Res 2011, 43(12):884-889.
68. Helfrich I., Scheffrahn I., Bartling S., Weis J., von Felbert V., Middleton M., et al. Resistance to antiangiogenic therapy is directed by vascular phenotype: vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010, 207(3):491-503.
69. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8(8):592-603.
70. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160(3):985-1000.
71. Song S., Ewald A.J., Stallcup W., Werb Z., Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7(9):870-879.
72. Hasumi Y., Klosowska-Wardega A., Furuhashi M., Ostman A., Heldin C.H., Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007, 121(12):2606-2614.
73. Sennino B., Falcon B.L., McCauley D., Le T., McCauley T., Kurz J.C., et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007, 67(15):7358-7367.
74. Nisancioglu M.H., Mahoney W.M., Kimmel D.D., Schwartz S.M., Betsholtz C., Genove G. Generation and characterization of rgs5 mutant mice. Mol Cell Biol 2008, 28(7):2324-2331.
75. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453(7193):410-414.
76. Simonavicius N., Robertson D., Bax D.A., Jones C., Huijbers I.J., Isacke C.M. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 2008, 21(3):308-315.
77. Tidhar A., Reichenstein M., Cohen D., Faerman A., Copeland N.G., Gilbert D.J., et al. A novel transgenic marker for migrating limb muscle precursors and for vascular smooth muscle cells. Dev Dyn 2001, 220(1):60-73.
78. Goritz C., Dias D.O., Tomilin N., Barbacid M., Shupliakov O., Frisen J. A pericyte origin of spinal cord scar tissue. Science 2011, 333(6039):238-242.
79. Dulauroy S., Di Carlo S.E., Langa F., Eberl G., Peduto L. Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med 2012, 18(8):1262-1270.
80. LeBleu V.S., Taduri G., O'Connell J., Teng Y., Cooke V.G., Woda C., et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013, 19(8):1047-1053.